BioMarin Secures 20% U.S. Royalty on Ascendis' Yuviwel in Global Patent Settlement
BMRN sits 38% above its 52-week low of $49.259.
Summary
BioMarin entered a binding Term Sheet with Ascendis Pharma resolving all patent disputes, granting Ascendis a worldwide license in exchange for 20% U.S. and 18% EU/Brazil/South Korea royalties on Yuviwel net sales through May 2030.
Key Events · Legal and Risk Events · BMRN
-
Global Patent Settlement with Ascendis
On August 30, 2026, BioMarin and Ascendis Pharma entered a binding Term Sheet that resolves all pending patent litigation, including the ITC Section 337 investigation and cases in Brazil, Denmark, Germany, South Korea, and the Northern District of California.
-
Royalty Structure Secured
Ascendis will pay BioMarin a 20% royalty on U.S. net sales of Yuviwel and 18% on EU, Brazil, and South Korea net sales, retroactive to first commercial sale, until May 2030.
-
License Scope
The non-exclusive, worldwide, transferable license covers all current and potential indications for Yuviwel (TransCon CNP/navepegritide), including achondroplasia and hypochondroplasia, and combination use with other medicines.
-
Litigation Dismissal
All pending proceedings will be dismissed with prejudice, and Ascendis covenants not to challenge BioMarin's Patent Rights, with a mutual regulatory non-interference clause.
Analysis · BMRN · Life Sciences
Resolving all patent litigation with Ascendis Pharma, BioMarin secures a 20% royalty on U.S. net sales of Yuviwel and 18% on EU, Brazil, and South Korea sales until May 2030. The binding Term Sheet dismisses the ITC Section 337 investigation and all related cases, removing a major legal overhang while creating a recurring royalty stream from a competing achondroplasia therapy. This deal validates BioMarin's CNP patent portfolio and provides downside protection on VOXZOGO's competitive positioning.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.5% of the 1531 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMRN was trading at $67.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $49.26 to $70.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.